Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | TPMT | P51580 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5588225 | 0.77 | IMPDH2 (0.36) | IMPDH2 | |
| SCHEMBL13212272 | 0.75 | IMPDH2 (0.45) | IMPDH2SMN1; SMN2GPR35TSHRALDH1A1 | |
| SCHEMBL5589480 | 0.73 | IMPDH2 (0.44) | IMPDH2SMN1; SMN2GPR35TSHRALDH1A1 | |
| SCHEMBL5586669 | 0.72 | GRIN2D (0.38) | IMPDH2SMN1; SMN2PKMGPR35MAPT | |
| SCHEMBL5588912 | 0.72 | IMPDH2 (0.34) | IMPDH2SMN1; SMN2PKM | |
| SCHEMBL5587195 | 0.71 | KMT2A (0.36) | IMPDH2SMN1; SMN2 | |
| SCHEMBL5587433 | 0.70 | ESR1 (0.35) | IMPDH2SMN1; SMN2 | |
| SCHEMBL5588252 | 0.70 | SMN1; SMN2 (0.33) | IMPDH2SMN1; SMN2PKM | |
| SCHEMBL5589481 | 0.70 | IMPDH2 (0.48) | IMPDH2SMN1; SMN2PKMMAPTTSHR | |
| SCHEMBL5586711 | 0.69 | ESR1 (0.37) | IMPDH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | IMPDH2 4570/4885SMN1; SMN2 3076/4885PKM 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.